Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 1 of 85  
 
 
Protocol Title:  An Open -label, Single -arm Study to Characterize 
the Pharmacodynamics and Safety of Repeat 
Dose SP -102 (Dexamethasone S
odium Phosphate 
Injectable Gel) Administered by [CONTACT_55396][INVESTIGATOR_13873] 
I
njection in Subjects with Lumbosacral 
Radiculopathy 
Protoco l Number:  SP-102-03 
Clinical Phase:  2 
Protocol Version and Date:  Version 1.0, 08 Jun  2018  
US Investigational New 
Drug Number:   
Sponsor:  Semnur  Pharmaceuticals, Inc.  
[ADDRESS_814007] 
Mountain View , CA [ZIP_CODE] 
 
-CONFIDENTIAL-  
This document and its contents are the property of and confidential to Semnur Pharmaceuticals, 
Inc.  Any unauthorized copying or use of this document is prohibited. 
 
 
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 3 of 85 SYNOPSIS  
Protocol Title:  An Open -label, Single -arm Study t o Characterize the Pharmacodynamics and 
Safety  of Repeat Dose  SP-102 (Dexamethasone Sodium
 Phosphate Injectable Gel) 
Administered by [CONTACT_55396][INVESTIGATOR_613929]:  SP-102-03 
Study Center(s):  Up to 2 
Phase of Development:  2 
Objectives:  The primary  objective of the study is to characterize repeat dose 
pharmacodynamics (PD) of SP -102 (10 mg dexamethasone) a
dministered by 
[CONTACT_14198][INVESTIGATOR_613930]- pi[INVESTIGATOR_2117] -adrenal (HPA) 
suppression using plasma cortisol levels, white blood cell cou nt (WBC), and blood 
glucose.  
The secondary  objecti
ves of the study are to : 
• Evaluate the safety and tolerability of single and repeat dose SP -102 
(10 mg dexamethasone) administered by [CONTACT_14198][INVESTIGATOR_613931]
l radiculopathy.  
• Evaluate the anal
gesic effect on leg pain (as measured by [CONTACT_613979] [ NPRS ] in the affected leg ) following the  index 
(Treatment [T] 1)  and repeat (T2) injection s. 
Study Design:  This is an open -label, singl e-arm, repeat dose study to characterize the PD and 
safety/tolerability of SP -102 (10 mg dexamethasone
) administered by [CONTACT_14198][INVESTIGATOR_613932] (TF) or int erlaminar (IL) injection  under fluoroscopic 
guidance in subjects with lumbosacral radiculopathy.   
Subjects meeting the eligibility criteria will be enrolled in the study and receive  a 
single 2 -mL epi[INVESTIGATOR_613933]- 102 (10 mg dexamethason
e) in T1 (index 
injection ) an
d T2 (repeat injection ), separated by [ADDRESS_814008] 
been using opi[INVESTIGATOR_613934] 30 days 
prior to Screening (see Exclusion #12 ), may participate in the study  if they agree to 
discontinue the opi[INVESTIGATOR_613935]-scree ning informed consent form .  
The study will include a 21 -day screening per iod (Visit 1) , sequential treatments 
periods T1 and T2 , separated by 4 to 8 weeks ; each treatment peri od will consist of 
a Baseline Visit (Day 0), SP -102 injection  (Day 1), and  a 4-week follow -up period .  
Screening, Baseline, and follow -up visits will occur at the research site.   Subject s 
will stay i
n a restricted environment ) for each of [ADDRESS_814009] the restricted 
environment ) and resume normal activities each day after study  
procedures are performed.  The SP -[ADDRESS_814010]  dose during the stay in the restricted 
environment ( ), and at 3  outpatient follow -up visits (on Day  8, Day  15, and 
Day 28) after each injection.  The end of study (EOS) visit (Visit  19) is the final 
outpatient visit after the second injection .  If the subject is not eligible for T2 or 
chooses to withdraw from further participation  in the study , the subject will be 
scheduled for the EOS visit (Visit 19).  
From the time of 
informed consent to the EOS visit, each subject’s participation 
may last up to 15  weeks.  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 6 of 85 13. An epi[INVESTIGATOR_613936] 2 months prior to the Screening 
Visit.   
14. History of spi[INVESTIGATOR_613937], which may interfere with IL epi[INVESTIGATOR_195037], or plans to undergo spi[INVESTIGATOR_613938].   
15. Has donated blood exceeding 500 mL during the 45 days before Baseline 
Visit.  
16. Use of any investigational drug or device within 30 days prior to the Screening Visit or is scheduled to receive an investigational drug other 
than study drug during the course of this study.   
17. If female, are lactating/breastf eeding, plan to breastfeed, currently 
pregnant, or plan to become pregnant while participating in the study.  
18. Alcohol  dependence, drug abuse, or drug addiction within 1 year of the 
Screening Visit.  
19. Involvement in an ongoing worker’s compensation claim, disability claim, or litigation related to any pain problem, receiving payments for a settled 
claim, awaiting pending pa yment for a settled claim, or any secondary 
gain in the opi[INVESTIGATOR_871].  
20. The presence of any disorder, condition, laboratory abnormality, or circumstance (with the exception of the condition under study) as 
determined by a medical and psychiatr ic history, medical examination, 
electrocardiogram ( ECG ), serum chemistry, hematology, and urinalysis 
that, in the opi[INVESTIGATOR_871], has the potential to compromise subject safety, prevent study completion, and/or to have a confounding effect on  outcome measures . 
Investigational Product:  SP-102: dexamethasone sodium phosphate injectable gel, [ADDRESS_814011]:  None  
Duration of Treatment:  2 single injections of SP -102.  
Main Parameters to 
Measure Pharmacodynamics : The foll owing PD assessments will be performed during the study:  
• Cortisol  
• Fasting blood glucose  
• WBC 
• NPRS measuring current, worst, and average leg and back pain 
• Brief Pain Inventory (BPI -SF)  
Main Parameters of Safety: The following safety assessments will be pe rformed during the study: 
• Adverse events (AEs)  
• Vital signs  
• Body weight  
• Physical examinations  
• General neurological examination  
• Targeted neurological examination  
• 12-lead ECGs  
• Clinical laboratory tests ( serum chemistry, hematology, urinalysis , HIV, 
viral h epati tis screening, and coagulation tests ) 
• Serum or urine pregnancy tests  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 7 of 85 Pharmacodynamic  
Endpoints : • Dexamethasone- induced HPA suppression as measured by: 
o Observed total blood cortisol levels, change from baseline 
cortisol levels, and percent change from baseline cortisol levels  
o Observed glucose levels, change from baseline glucose levels, and percent change from baseline glucose levels  
o Observed white blood cell counts, change from baseline white blood cell counts, and percent change from baseline white blood cell counts  
• NPRS (average leg pain and back pain) and BPI -SF  
• Change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS (average leg pain and back pain) and BPI -SF over time following the index (T1) 
and repeat (T2) epi[INVESTIGATOR_260794], respectively  
• Percent change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS 
(average leg pain and back pain) and BPI -SF following the index (T1) and 
repeat (T2) epi[INVESTIGATOR_260794], respectively  
Safety Endpoints:  Safety endpoints are as follows:  
• Incidence of treatment -emergent AEs (TEAEs) and serious adverse events  
(SAEs)  
• Change from baseline in clinical laboratory parameters, vital sign 
measurements , ECG  findings, and physical examination parameters 
following each treatment   
Statistical Analyses:  No formal statistical power calculation was performed for this study; the sample size is based on clinical and practical considerations.  
TEAEs and SAEs, observed values and changes in clinical laboratory parameters, 
and vital signs will be summarized descriptively for each treatment.  Shifts in 
laboratory parameters , physical examination findings , general neurological 
examination findings, and targeted neurological examination findings will be 
summarized by [CONTACT_1570].  
Unless otherwise specified, baseline is defined as the last non -missing 
measurement taken prior to treatments T1 or T2 (reference start date).  This 
includes screening or unscheduled assessments that would have been performed no earlier than [ADDRESS_814012]-reference.  
Cortisol levels, WBC counts, and fasting blood glucose levels (observed, change 
from baseline, and percent change from baseline) will be summarized by [CONTACT_613980].  Dexamethasone- induced HPA 
suppression will be evaluated by [CONTACT_613981], 
glucose levels, and WBC count.  Other PD analyses may be performed as 
appropriate .  
For blood cortisol and glucose levels, and WBC counts (change ‐from ‐baseline), PD 
parameters, ie, area under the effect curve over 28 days (AUEC
28 days ) and 
maximum effect (E max) following the T1 (index) and T2 (repeat) injections  will be 
calculated.   
AUEC 28 days  is defined as the change from baseline (for cortisol,  glucose, and 
WBC) and calculated using linear trapezoidal summation from pre -dose to Day [ADDRESS_814013].  Estimates and 90% confidence intervals (CIs) will be fir st constructed in 
the logarithmic scale.  By [CONTACT_613982]- logarithms, estimates and CIs for the 
geometric means and ratios of geometric means will be calculated.  All CIs will be 2-sided.  
A lack of effect of repeat injection on the PD will be concluded if the 90% CIs for 
the ratio of T2 (repeat injection; Test) to T1 (index; Reference) for both AUEC
28 days  and E max are completely contained within the range of 80 to 125%.  
The pain assessment closest to and prior to dosing in each treatment period will be used as baseline for each treatment period.  The following pain -score endpoints 
will be summarized over time by [CONTACT_53846]:  
• NPRS  (average leg pain and back pain) and BPI -SF  
• Change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS (average 
leg pain and back pain) and BPI -SF over time following the index (T1) 
and repeat (T2) epi[INVESTIGATOR_260794], respectively  
• Percent change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS (average leg pain and back pain) and BPI -SF following the ind ex (T1) and 
repeat (T2) epi[INVESTIGATOR_260794], respectively  
 
  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814014] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ................................................14  
ADMINISTRATIVE STRUCTURE  .............................................................................................17  
1 INTRODUCTION  .................................................................................................................18  
1.1 Background ........................................................................................................................18  
1.1.1  Lumbosacral Radicular Pain  ......................................................................................18  
1.1.2  Epi[INVESTIGATOR_613939]  ........................................................................................................18  
1.1.3  SP-102 ........................................................................................................................20  
1.2 Preclinical Studies  ..............................................................................................................20  
1.3 Clinical Studies  ..................................................................................................................21  
1.4 Use of Epi[INVESTIGATOR_613940]  ..22 
1.5 Study Rationale ..................................................................................................................22  
1.6 Dose Rationale  ...................................................................................................................22  
1.7 Study Endpoint Rationale ..................................................................................................23  
1.8 Risks and Benefits for Subjects  .........................................................................................23  
2 STUDY OBJECTIVES  ..........................................................................................................24  
2.1 Primary Objective  ..............................................................................................................24  
2.2 Secondary Objectives  .........................................................................................................24  
3 INVESTIGATIONAL PLAN  ................................................................................................25  
3.1 Overall Study Design and Plan ..........................................................................................25  
3.2 Study Duration ...................................................................................................................26  
3.3 Selection of Study Population ............................................................................................26  
3.3.1  Inclusion Criteria  .......................................................................................................26  
[IP_ADDRESS]  Treatment 1 Inclusion Criteria  .......................................................................................... 26 
[IP_ADDRESS]  Treatment 2 Inclusion Criteria  .......................................................................................... 27 
3.3.2  Exclus ion Criteria  ......................................................................................................27  
3.3.3  Stoppi[INVESTIGATOR_1869] ...........................................................................................................29  
3.3.4  Removal of Subjects from Therapy or Assessment  ...................................................29  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 10 of 85 3.4 Treatments..........................................................................................................................30  
3.4.1  Details of Study Treatments  .......................................................................................30  
3.4.2  Dosage Schedule ........................................................................................................30  
3.4.3  Treatment Assignment  ...............................................................................................31  
3.4.4  Drug Packaging and Blinding ....................................................................................31  
3.4.5  Drug Inventory and Accountability ...........................................................................31  
3.4.6  Treatment Compliance  ...............................................................................................31  
3.4.7  Rescue Medication  .....................................................................................................31  
3.4.8  Prior and Concomitant Illnesses and Medications .....................................................32  
[IP_ADDRESS]  Prior and Concomitant Illnesses  ....................................................................................... 32 
[IP_ADDRESS]  Prior and Concomitant Medications  ................................................................................. 32 
[IP_ADDRESS]  Prohibited Medications and Substances  ............................................................................ 32 
3.4.9  Allowed Medications and Treatments .......................................................................33  
3.5 Assessments .......................................................................................................................34  
3.5.1  Schedule of Assessments ...........................................................................................34  
3.5.2  Study Procedures .......................................................................................................39  
[IP_ADDRESS]  Prescreening  ...................................................................................................................... 39 
[IP_ADDRESS]  Visit 1 – Screening Visit – (Day -21 to Day -1) ............................................................... 39 
[IP_ADDRESS]  Visit 2 – T1 Baseline Visit – Day 0  .................................................................................. 40 
[IP_ADDRESS]  Treatment 1  ....................................................................................................................... 40 
[IP_ADDRESS]  Visit 8 (Treatment 1, Day 8 ± 2 days)  .............................................................................. 42 
[IP_ADDRESS]  Visit 9 (Treatment 1, Day 15 ± 2 days)  ............................................................................ 42 
[IP_ADDRESS]  Visit 10 (Treatment 1, Day 28 ± 2 days)  .......................................................................... 43 
[IP_ADDRESS]  Telephone Contact  ............................................................................................................ 43 
[IP_ADDRESS]  Visit 11 (Treatment 2 Baseline)  ........................................................................................ 43 
[IP_ADDRESS]  Treatment 2  .................................................................................................................... 44 
[IP_ADDRESS]  Visit 17 ( Treatment 2, Day 8 ± 2 days)  .......................................................................... 46 
[IP_ADDRESS]  Visit 18 (Treatment 2, Day 15 ± 2 days)  ........................................................................ 46 
[IP_ADDRESS]  Visit 19/End of Study/Early Te r
mination (Treatment 2, Day 28 ± 2 days)  ................... 46 
3.5.3  Assessments for Early Termination  ...........................................................................47  
3.5.4  Pharmacodynamic Assessments  ................................................................................47  
[IP_ADDRESS]  Cortisol ............................................................................................................................. 47 
[IP_ADDRESS]  Glucose  ............................................................................................................................. 47 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 11 of 85 [IP_ADDRESS]  White Blood Cell Count  ................................................................................................... 48 
[IP_ADDRESS]  Numeric Pain Rating Scale  ............................................................................................... 48 
[IP_ADDRESS]  Brief Pain Inventory - Short Form  .................................................................................... 48 
3.5.5  Safety Assessments ....................................................................................................48  
[IP_ADDRESS]  Physical Examination  ....................................................................................................... 48 
[IP_ADDRESS]  General Neurological and Targeted Neurological Examinations:  .................................... 48 
[IP_ADDRESS]  Vital Signs and Body Weight  ........................................................................................... 49 
[IP_ADDRESS]  Electrocardiogram  ............................................................................................................. 49 
[IP_ADDRESS]  Laboratory Parameters  ...................................................................................................... 49 
[IP_ADDRESS]  Adverse Events ................................................................................................................. [ADDRESS_814015]  ............................................................................54  
4.2.3  Serious Adverse Events  .............................................................................................54  
4.3 Procedures for Documenting Pregnancy during the Study ................................................55  
5 DATA MANAGEMENT AND STATISTICAL ANALYSIS  ..............................................56  
5.1 Data Management Considerations  .....................................................................................56  
5.2 Statistical Considerations  ...................................................................................................56  
5.2.1  Sample Size Justification  ...........................................................................................56  
5.2.2  Study Data ..................................................................................................................56  
5.2.3  Analysis Methods.......................................................................................................57  
5.2.4  Analysis Populations ..................................................................................................57  
5.2.5  Demographic and Baseline Characteristics  ...............................................................58  
5.2.6  Pharmacodynamic Endpoints.....................................................................................58  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 12 of 85 5.2.7  Pharmacodynamic Analyses  ......................................................................................58  
5.2.8  Safety Analyses  ..........................................................................................................59  
[IP_ADDRESS]  Adverse Events ................................................................................................................. 59 
[IP_ADDRESS]  Laboratory Data  ................................................................................................................ 59  
[IP_ADDRESS]  Vital Signs ......................................................................................................................... 59 
[IP_ADDRESS]  Electrocardiographic Data ................................................................................................ 60 
[IP_ADDRESS]  Physical Examination Findings  ......................................................................................... [ADDRESS_814016]/Independent Ethics Committees  ....................................[ADDRESS_814017]  
ALT (SGPT)  alanine aminotransferase (serum glutamic pyruvic transaminase)  
AST (SGOT)  aspartate aminotransferase (serum glutamic oxaloacetic transaminase)  
AUC inf area under the effect time curve from time zero extrapolated to 
infinity  
AUEC28 days  area under the effect time curve  at [ADDRESS_814018]  
EOS  end of study 
ESI epi[INVESTIGATOR_613941]  
F Fahrenheit 
FAERS  FDA Adverse Event Reporting System 
FDA  Food and Drug Administration  
FSH follicle stimulating hormone 
g gram 
GCP  Good Clinical Practice  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 15 of 85 Abbreviation  Definition  
HbA1c  Hemoglobin A1c  
HIV human immunodeficiency virus 
HPA  hypothalamic- pi[INVESTIGATOR_2117] -adrenal 
IB Investigator’s Brochure  
ICF informed consent form 
ICH International Council on Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use  
IL interlaminar(ly)  
IM intramuscular(ly)  
IND Investigational New Drug  
INR International Normalization Ratio  
IP investigational product 
IRB institutional review board  
IV intravenous(ly) 
LFT liver function tests  
µg microgram  
µmol micromole  
MEDD  Mean Equivalent Daily Dose 
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram  
min minutes 
mITT  Modified intent- to-treat (dataset)  
mIU milli international unit  
mL milliliter  
mm millimeter 
mmHg  millimeters of mercury  
mRNA  messenger ribonucleic acid  
MRI  magnetic resonance imaging  
NPRS  Numeric Pain Rating Scale  
NSAID  nonsteroidal anti -inflammatory drug(s)  
OL open- label  
PD pharmacodynamic 
PT prothrombin time 
PTT partial prothrombin time  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814019] operating procedure 
T treatment 
TEAE  treatment -emergent adverse event  
TF transforaminal(ly)  
Tmax time to maximum concentration  
US [LOCATION_002]  
WBC  white blood cells  
WOCBP  women of childbearing potential  
  
 
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814020] is provided in a separate document . 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 18 of 85 1 INTRODUCTION  
1.1 Background 
1.1.1 Lumbosacral Radicul ar Pain  
Back pain is a widespread, debilitating disorder that results in an enormous socioeconomic 
burden.  The lifetime prevalence of low back pain ranges from 60% to 90%, a nd the annual 
incidence is ~5%  (Frymoyer-1988, Frymoyer-1992).   The annual cost to treat back pain has been 
estimated to exceed $100  billion, of which it is estimated that up to $[ADDRESS_814021] 
productivity ( Cleeland -1989) .   
A specific type of back pain in the distribution of lumbosacral nerves is known as lumbosacral 
radicular pain, which is frequently referred to as sciatica .  It is a common condition with a 
lifetime inc idence varying from 13% to 40% (Stafford -2007) .  The corresponding annual 
incidence of an epi[INVESTIGATOR_613942] 1% to 5% (Frymoyer-1988, 
Frymoyer-1992).   It is rarely diagnosed before the age of 20, peaks in incidence in the fifth 
decade of life and declines thereafter  (Frymoyer-1992) .   
Lumbosacral radicular pain  is believed to result most commonly from prolapsed disc material 
causing pain secondary to mechanical impi[INVESTIGATOR_277970]/or inflammation of the anterior primary rami of lumbar nerve roots .  Histological changes have been first described in 1951 
(Lindahl-1951).   Approximately 90% of cases of lumbosacral radicular pain are caused by a 
herniated disc with nerve root compression, with various other etiologies accounting for the remaining 10% of the cases ( Stafford -2007, Valat -2010) .  
There are several conservative treatments for lumbosacral radicular pain, each with varying levels of effectiveness.  These therapeutic approaches include bed rest, staying active (in contrast 
to bed rest), analgesic or non- steroidal anti-inflammatory drugs (NSAIDs), acupuncture, spi[INVESTIGATOR_613943], traction therapy, physical therapy, behavioral treatment, and epi[INVESTIGATOR_158419]  (ESIs) ( Frymoyer-1992, Koes -2007, Valat -2010) .  The initial phase of sciatica 
frequently responds to conservative management with no intervention.  For example, in a study 
of more than 208 subjects with obvious symptoms and signs of a lumbosacral radicular pain  
([ADDRESS_814022] sacral vertebra), treated with nonsteroidal anti -inflammatory drug 
pi[INVESTIGATOR_613944], 70% in active group reported a marked reduction in back and leg pain and improved functionality within 4 weeks and 60% had returned to work at that point in time.  
However, approximately 30% of subjects in both groups still complained of back pain and 19.5% were out of work after 1 year  (Weber -1993) .  When these more conservative treatments for 
lumbosacral radicular pain are ineffective, ESIs  or surgical interventions are commonly used. 
Epi[INVESTIGATOR_613945] 19 01 via the sacral hiatus for lumbosacral 
radicular pain  (Nelson -2001) .  In the 1950s, physicians began injecting corticosteroids into the 
epi[INVESTIGATOR_613946] a treatment for lumbosacral radicular pain  (Barry -1962, 
Benzon-2015) .  
1.1.[ADDRESS_814023] controlled trial evaluating ESIs was performed in 1970  (Sullivan -1995)  and since then 
there have been many controlled trials evaluating the effectiveness of different corticosteroids injected into the epi[INVESTIGATOR_613947] .  Despi[INVESTIGATOR_613948], anatomical region of injection, control group, injectate characteristics, and 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814024] short -term benefit in selected people ( Cohen-2013) .   
The mechanisms by [CONTACT_613983], but it is 
established that corticosteroids inhibit phospholipase A2, which catalytically hydrolyzes the 
bond converting membrane phospholipi[INVESTIGATOR_613949] 
(Cohen-2013) .  In addition to the anti- inflammatory effects, steroids may also inhibit pain via 
their ability to suppress ectopic discharges from injured nerve fibers and depress conduction in 
normal unmyelinated C fibers  (Devor -1985, Johansson-1990) .  Epi[INVESTIGATOR_613950] a standard treatment regimen for lumbosacral radicular pain  (Cohen-2013) .  The 
comparative effectiveness of the various treatment modalities has been a to pic that has been 
frequently addressed in the literature, but there is currently no [LOCATION_002] (US) Food and Drug 
Administration (FDA)- approved epi[INVESTIGATOR_613951].  
Epi[INVESTIGATOR_613952] a common procedure performed in the US for the management of lumbar radicular pain caused by [CONTACT_613984].  They have been shown 
effective in reducing pain, restoring function, reducing the need for other hea lth care, and 
avoiding surgery ( MacVicar -2013) .  Recent review of randomized controlled clinical trials  using 
ESIs for treatment of radicular pain demonstrate Level II clinical evidence of long -term benefits  
(Kaye -2015) .  ESIs are relatively safe pr ocedures, containing lower risks than opi[INVESTIGATOR_2538] 
(Cohen-2013) .  
Because injectable corticosteroids are not FDA ‐approved for this route of administration, the 
epi[INVESTIGATOR_613953] ‐label use of approved injectable steroid 
formulations.   
In 2009, the FDA began evaluating serious neurologic events associated with epi[INVESTIGATOR_613954].  Between 1997 and 2014, a total of 90 serious and sometimes fatal 
neurologic events were reported to the FDA Adverse Event Reporting System (FAERS), 
including cases of paraplegia, quadriplegia, spi[INVESTIGATOR_80557], and stroke.  There is concern that in glucocorticoids formulated as suspensions rather than solutions, particulate matter may 
pose an increased risk of embolism after inadvertent intravascular injection .  All catastrophic 
events (those resulting in permanent disability or death) reported to FAERS were associated with 
injection of a suspension, whereas only a few cases involving tempor ary symptoms were 
reported with glucocorticoid solutions ( Racoosin -2015).   In 2014, the FDA issued a requirement 
that all injectable glucocorticoid product labels carry a warning stating that “serious neurologic events, some resulting in death, have been reported with epi[INVESTIGATOR_80556]” 
and that the “safety and effectiveness of epi[INVESTIGATOR_613955]”  (Food and Drug 
Administration -2014) . 
The Anesthetic and Analgesic Drug Products Advisory Committee held a meeting on November 24‐ 25, 2014 to disc
uss the risk of serious neurologic adverse reactions associated with 
ESIs administered to reduce inflammation for pain management.  The Committee considered the 
efficacy of ESI and the overall risk ‐benefit balance of injecting steroids in the epi[INVESTIGATOR_613956] .  The committee acknowledged the benefits of ESIs.  The safety concerns are related to 
particulate -containing formulations leading to 131 neurologic al adverse events (AEs) , including 
41 cases of arachnoidit
is, identified by  [CONTACT_1622], and 700 cases of fungal meningitis following 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 24 of 85 2 STUDY OBJECTIVES  
2.1 Primary Objective  
The primary  objective of the study is to characterize repeat dose PD of SP -102 (10 mg 
dexamethas
one) administered by [CONTACT_14198][INVESTIGATOR_613957], WBC  count, and blood gl ucose.  
2.2 Secondary Objectives  
The secondary objectives of the study are to:  
• Evaluate the safety and tolerability of single and repeat dose SP -102 (10 mg 
dexame
thas
one) administered by [CONTACT_14198][INVESTIGATOR_613958]. 
•
 Evaluate t he analges
ic effect on leg pain (as measured by [CONTACT_5977] 
[NPRS]  in the affected leg ) following the index (Treatment [T] 1)  and repeat (T2) 
injection s. 
   
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 25 of 85 3 INVESTIGATIONAL  PLAN 
3.1 Overall Study Design and Plan   
This is an open -label, single- arm, repeat dose study to characterize the PD and safety/tolerability 
of SP -102 (10 mg dexamethasone) administered by [CONTACT_613985]
s with lumbosacral radiculopathy.  
Subjects meeting the eligibility criteria will be enrolled in the study and receive a single 2 -mL 
epi[INVESTIGATOR_613959] -102 ( 10 mg dexamethasone)
 in T1 (index injection) and T2 (repeat 
injection ), separat
ed by [ADDRESS_814025] bee
n using opi[INVESTIGATOR_613934] 30 days prior to 
Screening (see Exclusion #12), may participate in the study if they agree to discontinue the 
opi[INVESTIGATOR_613960] S creening Visit and sign the pre -screening informed consent form 
(ICF).  
The study will include a 21-day screening period (Visit 1), sequential treatments periods T1 and T2, separated by 4 to 8 weeks ; each treatment period will co nsist of a Baseline Visit (Day 0), 
SP-102 injection (Day 1), and a 4 -week follow-up period.  Screening, Baseline, and follow-up 
visits will occur at the research site.   Subjects will stay in a restricted environment ( ) for 
each of [ADDRESS_814026] the 
restricted environment ) and resume normal activities each day after study procedures are performed.  The SP- [ADDRESS_814027] dose 
during the stay in the restricted environment ( ), and a t 3 outpatient follow -up visits (on 
Day 8, Day 15, and Day 28) after each injection.  The end of study (EOS) visit (Visit 19) is the 
final outpatient visit after the second injection.  If the subject is not eligible for T2 or chooses to 
withdraw from further participation  in the study, the subject will be scheduled for the EOS visit 
(Visit 19).  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 28 of 85 disease) at the Screening or Baseline Visit that would preclude the use of dexamethasone 
in this study.   
4. Has a major psychiatric disorder not controlled with medication at the Screening or 
Baseline Visit that would interfere with clinical pain scores or participation in the trial.  
5. History of any disorder related to cortisol production (eg, hyper- or hypo-cortisolism, Cushing’s syndrome, pi[INVESTIGATOR_46608], Addison’s disease, Nelson syndrome) at the Screening or Baseline Visit.   
6. History of malignancy or evidence of malignancy or lymphoproliferative or neoplastic disease with the exception of successfully  treated basal or squamous cell carcinoma of 
the skin or cervical intraepi[INVESTIGATOR_613961] 5 years of the Screening Visit.   
7. History of allergy to corticosteroids or anaphylactoid reaction to any other drug at the Screening or Baseline Visit.  
8. Known  allergy or idiosyncratic (atopic) reaction to contrast agent, local anesthetic, 
dexamethasone, any ingredient listed as being present in a study formulation, or any other pain management compound likely to be prescribed in the study. 
9. Abnormalities in clin ical chemistry that would place the subject at undue risk after 
epi[INVESTIGATOR_86227], per the discretion of the principal investigator.  These 
abnormalities include but are not limited to:  
a. serum glutamic -oxaloacetic transaminase/aspartate aminotransferase (AST) or serum 
glutamic -pyruvic transaminase/alanine aminotransferase (ALT) ≥  3 times the upper 
limit of the reference range at the Screening Visit   
b. Coagulation abnormalities: INR > 1.5 or platelet count <
 100,000/mm3) 
c. HIV, Hepatitis B, or Hepatitis C virus infection 
10. Creatinine clearance < 60  mL/min as estimated by [CONTACT_3158] -Gault equation ( Appendix 
B) at the Screening Visit.  
11. Chronic use (ie, more than 5 consecutive days) of oral or parenteral steroid medication during t he 2 months prior to the Screening Visit and any oral or parenteral steroid 
medication in the 2 weeks prior to the Screening Visit or to the Baseline Visit.  
12. Regular use of high dose opi[INVESTIGATOR_2438] (> 30 mg morphine equivalents for more than 2 days per week) in th e 30 days prior to the Screening Visit (Appendix C ).  The subject must 
agree to discontinue all opi[INVESTIGATOR_613962] . 
13. An epi[INVESTIGATOR_613963] 2 months prior to the Screening Visit.   
14. History of spi[INVESTIGATOR_613937], which may interfere 
with IL  epi[INVESTIGATOR_195037], or plans to undergo spi[INVESTIGATOR_613964].   
15. Has donated  blood exceeding 500 mL during the 45 days before Baseline Visit.  
16. Use of any investigational drug or device within 30 days prior to the Screening Visit or is 
scheduled to receive an investigational drug other than study drug during the course of this study.   
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 29 of 85 17. If female, are lactating/breastfeeding, plan to breastfeed, currently pregnant, or plan to 
become pregnant while participating in the study. 
18. Alcohol dependence, drug abuse, or drug addiction within 1 year of the Screening Visit. 
19. Involvement in an ongoing worker’s compensation claim, disability claim, or litigation 
related to any pain problem, receiving payments for a settled claim, awaiting pending 
payment for a settled claim, or any secondary gain in the opi[INVESTIGATOR_871]. 
20. The presence of any  disorder, condition, laboratory abnormality, or circumstance (with 
the exception of the condition under study) as determined by a medical and psychiatric history, medical examination, electrocardiogram ( ECG), serum chemistry, hematology, 
and urinalysis that, in the opi[INVESTIGATOR_871], has the potential to compromise 
subject safety, prevent study completion, and/or to have a confounding effect on outcome 
measures. 
3.3.[ADDRESS_814028] (AESI) (Section  4.2.2)  precludes the 
subject from receiving a repeat injection.  Three occurrences of the AESI of the same type across the study will trigger stoppi[INVESTIGATOR_405110] a safety review.  
3.3.[ADDRESS_814029] completed the study when he or she completes the 
Visit 19 (End of Study [E OS]/Early Termination [ ET]) visit.  If a subject is discontinued at any 
time after rando mization into  the study, the investigator will make every effort to follow the 
subject and complete the  EOS /ET assessments as shown in Section  3.5.1.  Enrollment will 
continue until [ADDRESS_814030] each completed two SP-102 injections (T1 and T2).   
A termination electronic Case Report Form (eCRF) page should be completed for every subject 
who receives IP, whether the subject  completes the study  or not.  The reason for any early 
discontinuation should be indicated on this form .  The primary reason for a subject  discontinuing 
early  should be selected from the following standard categories of ET: 
• Adverse Event : Clinical or laboratory events occurred that, in the medical judgment of the 
investigator for the best int erest of the subject, are grounds for discontinuation.  This 
includes SAEs , nonserious AEs, and AESI s regardless of relation to the IP. 
• Death: The subject died. 
• Withdrawal of Consent : The subject desired to withdraw from further participation in the 
study in the absence of an investigator- determined medical need to withdraw .  If the 
subject gave a reason for withdrawing, it should be recorded in the eCRF. 
• Protocol Violation : The subject’s findings or conduct failed to meet the protocol entry 
criteria or failed to adhere to the protocol requirements (eg, drug noncompliance, failure 
to return for defined number of visits).  The violation necessitated early discontinued 
from the study. 
• Lost to Follow- Up: The subject stopped coming for visits and study personnel were 
unable to contact [CONTACT_423] . 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814031]’s participation in the study is terminated prematurely for any reason , the reason for 
such ET should be documented and the Visit 19 /EOS/ET procedures should be performed.  If the 
ET occurs prior to Visit  10, the subject should be encouraged to continue in the study until 
Visit 10, if possible.  Subjects who do not receive both T1 and T2 will be discontinued from the 
study and the Visit 19/EOS/ET procedures should be performed.  In case of  ET, the subject 
should be encouraged to return to the site for ET procedures, or failing a return visit, a telephone 
visit should be arranged to encourage the subject to complete the Visit 19/EOS/ET procedures 
(Section [IP_ADDRESS]).  
An EOS  eCRF page should be completed for every subject who receives IP , whether the subject 
completes the study  or not .  The reason for  any ET should be indicated on this form.  The primary 
reason for the ET should be selected as noted in Section 3.3.4.  
3.5.4 Pharmacodynamic Assessments  
[IP_ADDRESS] Cortisol 
Blood is collected to measure the level of the hormone cortisol in the blood, which may indicate 
problems with the adrenal glands or pi[INVESTIGATOR_304].  Ideally, this test should be perform ed at 
[ADDRESS_814032]; this is not required at Screening.  Cortisol will be measured 
from blood samples c ollected at Screening, Visit 3 through Visit 10, and Visit 12 through 
Visit 19.  NOTE: The Screening test result is to be compared to the local laboratory normal range 
for cortisol daily variation.  
[IP_ADDRESS] Glucose  
A glucose level measures the amount of sugar circu lating in the blood.  Accurate levels of 
glucose are measured from blood obtained in a fasting state ; therefore, the subject will undergo 
at least a [ADDRESS_814033] prior to this being tested at 8 am ; this is not required at Screening .  
Glucose will be measur ed at Screening, Visit 3 through Visit 10, and Visit 12 through Visit 19.  
NOTE: The Screening test result is to be compared to the local laboratory normal range for 
non-fasted glucose.  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 48 of 85 [IP_ADDRESS] White Blood Cell Count 
The WBC count tabulated the number of WBC circu lating in the blood.  WBC  will be measured 
at Screening, Visit 3 through Visit 10, and Visit 12 through Visit 19. 
[IP_ADDRESS] Numeric Pain Rating Scale   
The NPRS  (Appendix E ) is an 11-point scale ([ADDRESS_814034] pain imaginable ) that allows the subject to rate the severity of their pain intensity at 
various points in time  (Turk -2003) .  The subject will use the NPRS to record their current  pain , 
average pain in the past [ADDRESS_814035] 24 hours for both their affected 
leg(s) and back pain .  The NPRS will be collected at each study visit.  
[IP_ADDRESS] Brief Pain Inventory  - Short Form  
The BPI -SF (Appendix F ) is a [ADDRESS_814036] correlation; worst pain, r=0.93; usual pain, r=0.78; p ain now, 
r=0.59.  The BPI- SF will be collected all  study visit s except Screening . 
3.5.5 Safety Assessments  
[IP_ADDRESS] Physical Examination  
A complete physical examination, including examination of general appearance, skin, neck, eyes, ears, nose, throat, heart, lungs, abdomen, lymph nodes, extremities, and musculoskeletal  system, 
will be performed at Screening .  The Screening physical examination will also include an 
assessment of lumbosacral radiculopathy.  Specific musculoskeletal examination focusing on 
lumbar spi[INVESTIGATOR_613965], 
such as SI joints and trigger points, will be performed in standardized manner and recorded.  A 
physical examination will be done at Screening, T1 – Day 0, T1 – Day 28, and T2 – Day 28 (Visit 19/EOS/ET).  
[IP_ADDRESS] General Neurological and Targeted Neurological Examination s:  
A general neurological examination will include evaluation of mental status (awareness of person, place, and time), cranial nerves, motor function and balance, sensory exam (ability to feel), and reflexes.  A targeted neurological examination focusing on signs and symptoms of 
lumbosacral radiculopathy, including straight leg raise test, will be performed according to the checklist (see Appendix G ).  Both general and targeted neurological exams are to be performed 
by [CONTACT_405118], if possible.  Training for conducting 
examination will be available on video.  General and targeted neurological examinations will be 
performed pre -dose and post dose on T 1 – Day  1, pre-dose and post dose on T2 – Day 1 , and on 
T2 – Day 28 (Visit 19/EOS/ET).  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 49 of 85 [IP_ADDRESS] Vital Signs and Body Weight  
Vital signs will include systolic and diastolic BP and heart rate.  During the us ual clinic visits, 
the subject is to be seated for approximately [ADDRESS_814037] is in prone position 
on the fluoroscopy table.  Vital signs  will be recorded at each clinic visit and will be monitored  
within 15 min prior to the procedure, approximately every 5 min during the procedure ( prior to 
syringe removal ), and approximately every 15 min after for 60 min after the procedure.  Height 
(in inches without shoes) and weight (in pounds) will be recorded a t Screening.  Weight will also 
be recorded at T1 – Day 0 , T1 – Day 28, and T2 – Day 28 (Visit 19/EOS/ET).  
[IP_ADDRESS] Electrocardiogram  
Standard 12- lead ECGs will be measured  in triplicate on the site machines after the subject has 
been supi[INVESTIGATOR_1919] 5 min at Screening, Baseline, T1 – Day 28, and T2 – Day 28 
(Visit 19/EOS/ET) .  The ECG results will be documented in the eCRF.  
[IP_ADDRESS] Laboratory Parameters  
The following clinical laboratory tests are to be per formed at Screening , Baseline, T1 – Day 5, 
T1 – Day 28, T2  – Day 5, and T2 – Day 28 (Visit 19/EOS/ET) unless noted below :  
Hematology: Hemoglobin, hematocrit, red blood cell count, WBC  count (with 
differential [lymphocytes, neutrophils, eosinophils, basophils, and monocytes] ), and 
platelet count.   
Serum Chemistry:  albumin, alkaline phosphatase, AST , ALT , direct bilirubin, total 
bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase (Screening only), 
creatinine, gamma- glutamyl trans ferase, glucose, lactate dehydrogenase, potassium, 
sodium, and uric acid . 
Other tests:  HbA1c,  HIV, hepatitis B, and hepatitis C at Screening.  Coagulation tests at 
Screening  or Baseline : activated PTT, PT, and INR.  Coagulation tests may be repeated 
prior to the index and repeat injection, if deemed necessary by [CONTACT_737] . 
Urinalysis:  Dipstick analysis: color, turbidity, specific gravity, pH, glucose, protein, 
ketones, urobilinogen, bilirubin, blood nitrate, leukocyte esterase, and microscopic examination when indicated by [CONTACT_215890]. 
Urine drug screen:  Includes opi[INVESTIGATOR_858], barbiturates, benzodiazepi[INVESTIGATOR_1651], tricyclic 
antidepressants, cannabinoids, PCP , cocaine, ecstasy, and amphetamines.  A urine drug 
screen will be obtained at Screening, Baseline, and T1 – Day 28.  A urine drug screen 
may be repeated if deemed necessary by [CONTACT_737].   
WOCBP : Serum pregnancy test at Screening .  Urine pregnancy test at Baseline and at 
Visit 11 (T2 – Day 0).  A urine pregnancy test may be repeated if deemed necessary by 
[CONTACT_737].  
Laboratory samples will be analyzed by [CONTACT_12082] .  In the event of an unexplained 
clinically noteworthy abnormal laboratory test value, the test should be repeated immediately 
and followed up until it has returned to the normal ran ge and/or an adequate explanation of the 
abnormality is found. 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 50 of 85 [IP_ADDRESS] Adverse Events  
All AEs occurring after the subject signs the ICF through EOS /ET (Visit 19) will be recorded .   
See Section  [ADDRESS_814038] measurements frequently 
seen in radiculopathy s tudies.   
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 51 of 85 4 ADVERSE EVENT REPORTING 
Throughout the course of the study, after signing the ICF, all AEs will be monitored and 
recorde d on an AE eCRF, including the AE ’s description, start and end date, seriousness, 
severity, action taken, and relationship to the IP.  If AEs occur, the first concern will be the 
safety of the study subjects.  All AEs will be followed until reso lved or stable and the outcome 
documented on the eCRF. 
4.[ADDRESS_814039] a causal 
relationship with this treatment ( ICH- E2A-1994).   An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or disease 
temporally associated w ith the use of a medicinal product, whether considered related to the 
medicinal product or not. 
Medical interventions such as surgeries, diagnostic procedures, and therapeutic procedures are 
not AEs,  but the action taken to treat the medical condition.  They should be recorded as 
treatment of the AEs.  
4.1.2 Serious Adverse Events 
A serious adverse event (SAE) or reaction is any untoward medical occurrence that at any dose:  
• Results in death  
• Is life -threatening 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability or incapacity  
• Is a congenital anomaly or birth defect 
• Is an important medical event (eg, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias, or convulsions that do not result in 
hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse; malignancy tumors [histological ly different from primary tumor] ) 
Note: The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe .   
Medical and scientific judgment  should be exercised in deciding whether expedited reporti ng is 
appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_613966] d in the definition above .  These should 
also usually be considered serious. 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 52 of 85 Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059]; or 
development of drug dependency or drug abuse. 
Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  An 
SAE is not necessarily severe; eg, an overnight hospi[INVESTIGATOR_272] a diagnostic procedure must 
be reported as an SAE even though the occurrence is not medically serious.  By [CONTACT_344231], 
a severe AE is not necessarily serious: nausea of several hours’ duration may be rated as severe 
but may not be considered serious. 
4.1.3 Unexpected Adverse Drug Reactions 
An unexpected adverse drug reaction (ADR) is a reaction for which the nature or severity is not 
consistent with the applicable product information ( IB, SP102 -IB-2017) .  Until product 
information is amended, expedited reporting is required for additional occurrences of the reaction .  Reports that add significant information on specificity or severity of a known, already 
documented SAE constitute unexpected events.  For example, an event more specific or more 
severe than described in the IB would be considered “unexpected.”  Specific examples would be 
(a) acute renal failure as a labeled ADR with a subsequent new report of interstitial nephritis and 
(b) hepatitis with a first report of fulminant hepatitis.  
Guidance on reporting AEs and SAEs is described in Section  4.2. 
4.1.4 Abnormal Laboratory Values 
Any abnormality ( Appendix H ) in a laboratory value that is new in onset or which has worsened 
in severity or frequency from the baseline condition and meets 1 of the following criteria will be recorded on the AE pages of the eCRF: 
• Requires therapeutic intervention or diagnostic tests 
• Leads to discontinuation of IP  
• Has accompanying or inducing symptoms or signs 
• Is judged by [CONTACT_142922]  
4.1.5 Assessing Intensity and Relationship  
All AEs will be assessed on 2 descriptive parameters: intensity and relationship to  the IP: 
• Intensity refers to the severity of an event and references impact on a subject’s 
functioning. 
• Relationship refers to the likelihood that the event being assessed was caused by [CONTACT_33249]. 
Intensity  
Each AE will be classified according to Appendix H . 
When changes in the intensity of an AE occur more frequently than once a day, the maximum 
intensity for the experience should be noted.  If the intensity category changes over a number of 
days, those changes should be recorded separately (with distinct onset dates). 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814040]  
plausible association.  
Investigators are required to assess the causal relationship (ie, whether there is reasonable possibility that the study drug caused the event) using the following definitions: 
Unrelated:  A clinical event, including laboratory te st abnormality, with a temporal 
relationship to study drug administration that makes a causal relationship 
improbable, and/or in which other drugs, chemicals or underlying disease 
provide plausible explanations of the event. 
Possibly Related:  A clinical event , including laboratory test abnormality, with a reasonable 
time sequence to administration of the study drug, but that could also be 
explained by [CONTACT_9153].  Information on study drug causality may be lacking or unclear. 
Probably Related: A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the study drug, unlikely to be attributed 
to concurrent disease or other drugs or chemicals, and that follows a clinically rea sonable response on re- administration (rechallenge) or 
withdrawal (dechallenge) of the study drug. 
Definitely Related:  A clinical event, including laboratory test abnormality, with a temporal relationship to study drug administration that makes a causal relationship 
definite and is clearly related to use of the IP. 
When assessing the relationship to the IP, the following criteria will be considered:  
• Positive rechallenge  
• Positive dechallenge (resolution upon stoppi[INVESTIGATOR_484570] , in absence of other 
intervention or treatment) 
• Known class effect  
• Biological plausibility  
• Lack of alternative explanation—concomitant drug or disease 
4.[ADDRESS_814041] study visit will be 
recorded .  Any AEs occurring before  the start of treatment (ie, before the first dose of the IP)” 
will be recorded in the medical history .  Also, the sign, symptom, or disease present before 
starting the treatment period are only considered AEs if they worsen after starting the treatment 
period. 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814042] be reported in the eCRF within 24 hours of awareness following Investig
ator (or site) awareness of the information.   The Investigator should not delay 
reporting an SAE to obtain additional information.  Additional information, when available, 
should be reported to  by [CONTACT_405120]. 
If the investig
ator detects an SAE in a stu dy subject within [ADDRESS_814043] scheduled  study 
visit, and considers the SAE  related or possibly related to prior study treatment, the investigator 
should report it to sponsor/  
The sponsor or its 
representative will be responsible for determining and in turn, reporting SAEs 
to regulatory authorities per the applicable regulatory requirements. 
4.[ADDRESS_814044]  should be reported t o  
within 24 hours of becoming aware of the event using the pregnancy e CRF.   The investigator 
will also: (1) notify the subject ’s physician that the subject may have been treated with SP-102 
and (2) follow the progress of the pregnancy to term and document the outcome of the 
pregnancy.  Pregnancy outcome information should be forwarded to sponsor/  when 
available. 
 
Any pregna
ncies will
 be followed through delivery or premature termination.  If a subject 
becomes pregnant during the study, any complications of that pregnancy such as abortion (spontaneous or induced), premature birth, or congenital abnormality will be captured as SAEs.  
In the event the e CRF system is unavailable, a back -up paper Pregnancy Reporting Form will be 
available for site staff to complete following reporting guidelines as outlined in Section 4.2.2. 
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814045] non -missing measurement taken prior 
to treatments T1 or T2 (reference start date).  This includes screening or unscheduled 
assessments that would have been performed no earlier than [ADDRESS_814046] -reference.  
For vital signs p arameters, an assessment performed on reference start date with time point 
marked as “pre- dose” will be considered as baseline.  
For cortisol suppression, glucose, and white blood cell counts, baseline is defined as the last non-missing value obtained prior to T1 or T2, which is T1/T2 Day [ADDRESS_814047] non -missing value obtained prior to T1 or T2, which is 
T1/T2 Day [ADDRESS_814048] 1 postdose PD assessment result  without any protocol deviations available in 
either T1 or T2.   
The Complete Analysis population is defined as all enrolled subjects who receive only one 
SP-102 injection who complete T1 – Day  28 plus those subjects who receive two SP -102 
injections who complete T2 – Day  28.  
Protocol deviations should be collected by [CONTACT_613986], such as 
those who: 
• Entered the study even though they did not s atisfy the entry criteria;  
• Developed withdrawal criteria during the study but were not withdrawn; 
• Received the incorrect dose;  
• Received an excluded concomitant treatment.  
Major protocol violations that impact the PD analysis may lead to exclusion from the PD  
population.  Full details regarding these will be provided in the SAP. 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814049] demographics and baseline 
characteristics and will be summarized using  descriptive statistics, but no formal statistical 
analysis testing will be performed.  
5.2.6 Pharmacodynamic Endpoint s  
• Dexamethasone-induced HPA suppression as measured by: 
o Observed total blood cortisol levels, change from baseline cortisol levels, and 
percent change from b aseline cortisol levels  
o Observed glucose levels, change from baseline glucose levels, and percent change 
from baseline glucose levels  
o  Observed white blood cell counts, change from baseline white blood cell counts, 
and percent change from baseline white bl ood cell counts 
• NPRS (average leg pain and back pain) and BPI- SF  
• Change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS (average leg pain and back pain) and BPI-SF over time following the index (T1) and repeat (T2) epi[INVESTIGATOR_613967], respectively  
• Percent change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS (average leg pain 
and back pain) and BPI-SF following the index (T1) and repeat (T2) epi[INVESTIGATOR_260794], respectively  
5.2.7 Pharmacodynamic Analyses 
All PD analyses will use the PD population as the primary analysis population.   
Cortisol levels, WBC counts, and fasting blood glucose levels (observed, change from baseline, and percent change from baseline) will be summarized by [CONTACT_613987].  Dexamethason e-induced HPA suppression will be evaluated by [CONTACT_613988], blood glucose levels, and WBC count.  Other PD analyses 
may be performed as appropriate.  For these PD endpoints, the pre-dose morning values will be 
determined for each subject as a Baseline for each treatment and the data will be presented as observed value, change from baseline, and as a percent of Baseline value.   
The following pain- score endpoints will be summarized over time by [CONTACT_33344]:  
• NPRS (average leg pain and back pain) and BPI- SF  
• Change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS (average leg pain and back pain) and BPI-SF over time following the index (T1) and repeat (T2) epi[INVESTIGATOR_260794], respectively  
• Percent change from T1 Day 0 and T2 Day 0 through Day 28 in NPRS (average leg pain 
and back pain) and BPI-SF following the index (T1) and repeat (T2) epi[INVESTIGATOR_260794], respectively  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 59 of 85 For blood cortisol and glucose levels, and WBC counts (change ‐from ‐baseline), PD parameters, 
ie, area under the effect curve over 28 days (AUEC 28 days ) and maximum effect ( Emax) following 
the T1 (index) and T2 (repeat) injections  will be calculated.   
AUEC 28 days  is defined as the change from baseline (for cortisol,  glucose, and WBC) and 
calculated using linear trapezoidal summation from pre -dose to Day [ADDRESS_814050].  Estimates and 
90% confidence intervals (CIs) will be first constructed in the l ogarithmic scale.  By [CONTACT_613989]-logarithms, estimates and C Is for the geometric means and ratios of geometric means will be 
calculated.  All C Is will be [ADDRESS_814051] of repeat injection on the PD will be concluded if the 90% CIs for the ratio of T2 
(repeat injection; Test) to T1 (index; Reference) for both AUEC 28 days  and E max are completely 
contained within the range of 80 to125%. 
5.2.8 Safety Analyses 
Safety endpoints are as follows: 
• Incidence of treatment -emergent adverse events (TEAEs) and SAEs  
• Change from baseline in clinical laboratory parameters, vital sign measurements, ECG  
findings, physical examination, general neurological examination  findings, and targeted 
neurological examination findings following each treatment 
[IP_ADDRESS] Adverse Events  
All AEs will be coded using the most current version of MedDRA.  TE AEs and SAEs will be 
summarized descriptively for each treatment.   
[IP_ADDRESS] Laboratory Data 
Mean changes from Baseline at each post -baseline time point for each laboratory variable will be 
presented .  In addition, each reading will be class ified as below, within, or above normal range, 
based on ranges supplied by [CONTACT_405121].  Shift tables for the Baseline and follow-up 
measurements will be presented.  
[IP_ADDRESS] Vital Signs  
Summary stat istics for the absolute vital sign value and the changes from B aseline will be 
presented by [CONTACT_353559], for each of the following vital signs: 
• Systolic blood pressure (mmHg) 
• Diastolic blood pressure (mmHg) 
• Heart rate (bpm)  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 60 of 85 Vital sign va lues will be categorized  into the following potential clinical concern categories if 
applicable and summarized. 
Vital Sign  Potential Clinical Concern Categories  
Systolic blood pressure  ≥ 160 mmHg  
Diastolic blood pressure  ≥ 100 mmHg  
Heart rate  < 60 or >  100 bpm  
[IP_ADDRESS] Electrocardiographic Data  
A listing of 12- lead ECG parameter results will be presented .  Shifts in ECG parameters will be 
summarized by [CONTACT_613990].  
[IP_ADDRESS] Physical Examinat ion Findings  
Shifts in physical examination findings will be summarized by [CONTACT_613991] a physical examination was performed. 
5.2.9 Interim  Analyses 
No interim analysis is planned for this study.    
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 61 of 85 6 STUDY MANAGEMENT 
6.1 Ethics  and Consent  
6.1.1 Regulat ions and Guidelines  
The study will be performed in accordance with this protocol,  US investigational new drug 
(IND) regulations (21 CFR 312), ICH guidelines for Good Clinical Practice  (GCP)  
(ICH- E6-1996),  the regulations on electronic records and electronic signature (21 CFR 11), and 
the most recent guidelines of the Declaration of Helsinki.   
6.1.[ADDRESS_814052]/Independent Ethics Committees  
Conduct of the study must be approved by [CONTACT_613992] .  Approval is 
required for the study protocol, protocol amendments, ICFs , subject information sheets, and 
advertising materials .  No IP will be shipped to a site until written IRB authorization has been 
received by [CONTACT_230025].  
6.1.[ADDRESS_814053]  and (if applicable) appointed guardian are aware of the potential risks, 
inconveniences, or adverse effects that may occur .  Subjects should be informed that they may 
withdraw from the study at any time .  They will receive all information that is required by 
[CONTACT_310189].  The principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a designated representative 
will provide the sponsor or its representative with a copy of the IRB -approved ICF  before the 
start of the study. 
6.2 Discontinuation of the Study by [CONTACT_613993].  A site that does not recruit at a reasonable rate may be 
discontinued.  Should the study be terminated, and/or the site closed for whatever reason, all documentation and IP  pertaining to the study must be returned to the sponsor or its 
representative.  
6.3 Study Documentation 
By [CONTACT_2960] a copy of Form FDA 1572, the principal investigator [INVESTIGATOR_33299]/she has received a copy of the IB  on SP-102 and assures the sponsor that he/she will comply with the 
protocol and the provisions stated in Form FDA 1572.  No changes in this protocol can be made without the sponsor’s written approval.  
6.[ADDRESS_814054] been processed correctly .  Remote and on- site review of eCRFs 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 62 of 85 will include a review of forms for completeness and clarity, and consistency with electronic or 
paper so urce documents (if used) for each subject .   
Medical advisors and CRAs  or assistants may request to witness subject evaluations occurring as 
part of this protocol.  The investigator and appropriate personnel will be periodically requested to attend meeting s/workshops organized by [CONTACT_88466].  
The study may be subject  to audit by [CONTACT_613994].  If such an audit 
occurs, the investigator must agree to allow access to required subject records.  By [CONTACT_130720], the investigator grants permission to personnel from the sponsor, its representatives, 
and appropriate regulatory authorities, for on- site monitoring of all appropriate study 
documentation, as well as on- site review of the procedures employed in eCRF generation, where 
clinically appropriate.  
6.[ADDRESS_814055] arrange for retention of study records at the site for 2 years after the IP’s 
New Drug Application is approved or the IND is withdrawn, as required by [CONTACT_1260].  
The investigator should take measures to prevent accidental or premature destruction of these documents. 
6.6 Use of Study Findings  
By [CONTACT_33351], the investigator agrees to the use of results of the study for the 
purposes of national and international registration .  If necessary, the authorities will be notified 
of the investigator’s name, address, qualifications, and extent of involvement.  Reports covering 
clinical and biometric aspects of the study will be prepared by [CONTACT_613995].  
6.7 Publications  
As a multicenter trial, the sponsor intends to publish clinical data from all centers participating in the investigation .  A publication committee selected by [CONTACT_613996] .  In conformity with the U niform 
Requirements for M anuscripts Submitted to B iomedical Journals published by [CONTACT_18037], investigators whose contribution consists solely  in the 
collection of data will not be named individually as authors ( Kassirer -1991) .  Rather, those 
investigators will receive a collective authorship and will be identified in a note.  
Individual investigators and/or their associates subsequently may publish additional findings of 
this study in scientific journals or present them at scientific meetings, if  the sponsor is given 
ample opportunity to review any proposed abstract, manuscript, or slide presentation before its submission .  This review is required to ensure that the sponsor is aware of all written and oral 
presentations of the data and does not imply any editorial review or restriction of the contents of 
the presentation or use. 
  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-[ADDRESS_814056] RW,  Tryba M,  Yuan, C.  ASRA Practice Advisory: 
Anticoagulation 3rd Edition: Regional Anesthesia and Pain Medicine. January/February 2010 
- Volume 35 - Issue 1 - pp 6 4-101.  doi: 10.1097/AAP.0b013e3181c15c70. 
2. Barry PJ, Kendall PH.  Corticosteroid Infiltration of the Extradural S pace.  Ann Phys Med.  
1962;6:267-273. 
3. Benzon HT, Huntoon MA, Rathmell JP.  Improving the Safety of Epi[INVESTIGATOR_613968]. JAMA 2015 May 5;313(17):1713-4.  
4. Canale L .  [Epi[INVESTIGATOR_613969]] .  Gazz 
Med Ital.  1963;122:210-213. 
5. Cohen SP, Bicket MC, Jamison D, et al.  Epi[INVESTIGATOR_613939]: A Comprehensive, 
Evidence- Based Review .  Reg Anesth Pain Med.  2013;38(3):175-200. 
6. Cleeland CS.   Measurement of pain by [CONTACT_208816].  In: Chapman CR, Loeser JD (Eds.).  
Advances in Pain Research and Therapy, Volume 12: Issues in Pain Measurement.  Raven 
Press, [LOCATION_001]; 1989:391-403. 
7. Devor M, Govrin-Lippmann R, Raber P .  Corticosteroids Suppress Ectopic Neural Discharge 
Originating  in Experimental Neuromas.  Pain .  1985;22(2):127-137. 
8. Dawley JD, Moeller -Bertram T, Wallace MS, Patel PM., Intra -arterial injection in the rat 
brain: evaluation of steroids used for tr ansforaminal epi[INVESTIGATOR_71543].  Spi[INVESTIGATOR_050]  (Phila Pa 1976) .  2009 
Jul 15;34(16):1638-43.  doi: 10.1097/BRS.0b013e3181ac0018. PMID: 19770605.  
9. El-Yahchouchi C, G eske JR, Carter RE, et al .  The N oninferiority of the Nonparticulate 
Steroid Dexamethasone vs the Particulate Steroids Betamethasone and Triamcinolone in 
Lumbar Transforaminal Epi[INVESTIGATOR_613968] .  Pain Med.  2013;14(11):1650-1657. 
10. Food and Drug Administration.  Guidance for Industry Electronic Source Data in Clinical Investigations.  September 2013.  
11. Food and Drug Administration.  FDA Drug Safety Communication: FDA Requires Label 
Changes to Warn of Rare but Serious Neurologic Problems a fter Epi[INVESTIGATOR_613970] .  April 23, 2014 (http://www.fda.gov/Drugs/DrugSafety/ucm394280.htm). 
12. Frymoyer JW.  Back Pain and S ciatica.  N Engl J Med.  1988;318(5):291-300. 
13. Frymoyer JW.  Lumbar Disk D isease: Epi[INVESTIGATOR_623].  Instr Course Lect .  1992;41:217-223. 
14. Grady JA, 2008: Thesis, Pharmacokinetics and Pharmacodynamics of Oral Dexamethasone 
in Healthy Horses.  Kansas State University.  
15. International Conference on Harmonisation.  Guideline for Good Clinical Practice , ICH E 6.  
June 10, 1996. 
16. Internationa l Conference on Harmonisation.  ICH Harmonised Tripartite Guideline Clinical 
Safety Data Management: Def initions a nd Standards for Expedited Reporting E2A.  October 
27, 1994. 
17. Iverson C, et al .  American Medical Association Manual of Style, 10
th Edition .  [LOCATION_001], 
NY: Oxford University Press, Inc.; 2007. 
Semnur Pharmaceuticals,  Inc.  Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 64 of 85 18. Johansson A, Hao J, Sjolund B.  Local corticosteroid application blocks transmission in 
normal nociceptive C- fibres.   Acta Anaesthesiol Scand.  1990;34(5):335-338. 
19. Kassirer JP, Angell M.  On Authorship and Acknowledgments.  N Engl J Med 1991;325(21): 
510-12.  
20. Kaufmann TJ, Geske JR, Murthy NS, et al.  Clinical Effectiveness of Single Lumbar 
Transforaminal Epi[INVESTIGATOR_613968] .  Pain Med .  2013;14(8):1126-1133. 
21. Kaye AD, Manchikanti L, Abdi S, Atluri S, Bakshi S, Benyamin R, Boswell MV, Buenaventura R, Candido KD, Cordner HJ, Datta S, Doulatram G, Gharibo CG, Grami V, 
Gupta S, Jha S, Kaplan ED, Malla Y, Mann DP, Nampi[INVESTIGATOR_613971], Racz G, Raj  P, Rana 
MV, Sharma ML, Singh V, Soin A, Staats PS, Vallejo R, Wargo BW, Hirsch JA Efficacy of Epi[INVESTIGATOR_613972]: A Best Evidence Synthesis.  Pain 
Physician 2015; 18:E939-E1004 • ISSN 2150-1149 
22. Kennedy DJ, Plastaras C, Casey E, et al .  Comparative Effectiveness of Lumbar 
Transforamin al Epi[INVESTIGATOR_613968] w ith Particulate Versus Nonparticulate 
Corticosteroids for Lumbar Radicular Pain due t o Intervertebral Disc Herniation: A 
Prospective, Randomized, Double-Blind Tri al.  Pain Med.  2014;15(4):548-555. 
23. Koes BW, van Tulder MW, Peul WC.  Diagnosis and T reatment of Sciatica.  BMJ .  
2007;334(7607):1313-1317. 
24. Lindahl O, Rexed B.  Histologic C hanges in Spi[INVESTIGATOR_613973].  Acta Orthop Scand.  1951;20(3):215-225. 
25. Ma V, Shakir A.  The Impact of Type 2 Diabetes on Numeric Pain Score Reduction 
Following Cervical Transforaminal Epi[INVESTIGATOR_613968] .  Skeletal Radiol .  
2013;42(11):1543-1547. 
26. MacVicar J, King W, Landers MH, Bogduk N.  The Effectiveness of Lumbar Transforaminal 
Injection of Steroids: A Comprehensive Review w ith Systematic Analysis of The Published 
Data .  Pain Med.  2013;14(1):14-28. 
27. Manchikanti L, Benyamin RM.  Key Safety Considerations when Administering Epi[INVESTIGATOR_613974] .  Pain Manag.  2015;5(4):261-272. 
28. Nelson DA, Landau WM.  Intraspi[INVESTIGATOR_613975]: History, Efficacy, Accidentality, And 
Controversy with Review of United State s Food and Drug Administration Reports.  J Neurol 
Neurosurg Psychiatry.  2001;70(4):433-443. 
29. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic Dose Ratios for Opi[INVESTIGATOR_2438]. A Critical Review and Proposals for Long- Term Dosing. J Pain Symptom Manage . 
2001;22(2):672-687. 
30. Racoosin JA, Seymour SM, Cascio L, Gill R.  Serious Neurologic Events after Epi[INVESTIGATOR_613976]- The FDA's Risk Assessment .  N Engl J Med .  2015 Dec 
10;373(24):2299-301.  doi: 10.1056/NEJMp1511754.  Epub [ADDRESS_814057] 7.   
31. Rathmell JP, Benzon HT, Dreyfuss P, et al .  Safeguards t o Prevent Neurologic Complications 
after Epi[INVESTIGATOR_613968]: Consensus Opi[INVESTIGATOR_613977] A Multidisciplinary Working 
Group and National Organizations .  Anesthesiology 2015;122:974-84.  
Semnur Pharmaceuticals,  Inc.  Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 65 of 85 32. Semnur Pharmaceuticals .  SP-102 (10mg dexamethasone) Investigator Brochure.  2nd ed.  
2017. 
33. Stafford MA, Peng P, Hill DA.  Sciatica: A Review o f History, Epi[INVESTIGATOR_623], Pathogenesis, 
and the Role of Epi[INVESTIGATOR_225190] i n Management .  Br J Anaesth .  
2007;99(4):461-473. 
34. Sullivan MJ L, Bishop SR, Pi[INVESTIGATOR_8331] J.  The Pain Catastro phizing Scale: Development and 
Validation.  Psychological Assessment  1995; 7: 524-532. 
35. Troshin VD, Iskanderova AA.  Treatment of Lumbosacral Radiculitis with Epi[INVESTIGATOR_613978] .  Zh Nevropatol Psikhiatr Im S Korsakova .  
1970;70(7):1010-1013. 
36. Turk DC, Dworkin RH, Allen RR, et al.  Core Outcome Domains for Chronic Pain Clinical 
Trials : IMMPACT Recommendations.  Pain .  2003;106(3):337-345. 
37. Valat JP, Genevay S, Marty M, Rozenberg S, Koes B.  Sciatic a.  Best Pract Res Clin 
Rheumatol.  2010;24(2):241-252. 
38. Weber H, Holme I, Amlie E.  The Natural Course of Acute Sciatica with Nerve Root 
Symptoms in a Double-Blind Placebo-Controlled Trial Evaluating t he Effect of Pi[INVESTIGATOR_18234] .  
Spi[INVESTIGATOR_050] (Phila Pa 1976).  1993;18(11):1433-1438. 
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 66 of 85 8 APPENDICES  
Appendix A  BMI Table  
 
 
  
 
  
 
  
 
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 76 of 85 Appendix H  Toxicity Grading Scale for Healthy Adult and Adolescent Vo lunteers 
Enrolled in Preventive Vaccine Clinical Trials.  
 
   
     
    
    
  
              
           
            
 
               
           
        
    
      
  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 77 of 85  
   
   
     
      
         
       
       
    
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 78 of 85  
   
        
       
              
                    
               
              
              
            
  
              
            
                
                
           
                  
             
               
        
            
            
              
                 
               
              
             
            
               
              
               
            
            
 
                 
  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 79 of 85 
   
            
             
            
                
    
   
            
            
              
             
              
                
    
              
              
            
             
             
     
           
             
             
              
            
      
               
              
             
               
             
              
               
           
             
              
             
             
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 80 of 85 
   
                 
                
             
              
  
               
               
              
             
          
     
             
   
  
            
          
       
    
  
          
      
         
  
 
          
       
    
                  
     
                 
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 81 of 85 
   
              
 
  
      
        
           
   
 
         
   
 
          
    
 
 
        
    
 
 
       
    
  
        
 
           
           
                
          
             
 
  
          
             
        
 
                 
          
    
  
  
 
            
       
        
    
   
          
      
 
          
      
 
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 82 of 85 
   
            
 
 
              
          
       
   
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 83 of 85 
   
     
              
          
       
        
     
 
        
        
        
          
        
   
       
      
 
       
   
         
 
        
          
        
        
 
           
 
      
        
                
   
               
   
               
       
   
                   
     
    
                  
                 
              
                
                
                     
        
         
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 84 of 85 
   
          
   
 
          
          
     
           
          
     
        
           
       
         
         
          
                 
   
                   
   
        
           
   
  
 
                   
              
          
           
   
  
      
 
      
 
           
        
      
 
                 
              
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-03 
  Version 1.0, 08 Jun  2018 
 
Confidential  Page 85 of 85  
   
    
          
 
              
   
         
 
             
     
               
  
   
 
             
      